March 1, 2016 Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea
February 17, 2016 Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
February 16, 2016 Synthetic Biologics to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare Conference
February 2, 2016 Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
January 19, 2016 Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
December 8, 2015 Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
